Prof. Dr. med. et phil. nat. Markus Jörger
Oberarzt Onkologie/Hämatologie
Mitarbeiter Wissenschaftliche Module CTU (Klinische Pharmakologie)
Leitende(r) Arzt/Ärztin
Medizinische Onkologie und Hämatologie · Dept. I
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis
Jörger M, Matter-Walstra K, Früh M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis. Ann Oncol 2012; 22:567-574.
01.01.2012Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis
01.01.2012Ann Oncol 2012; 22:567-574
Jörger Markus, Matter-Walstra K, Früh Martin
A population-based study on the implementation of treatment recommendations for chemotherapy in early breast cancer
Jörger M, Thürlimann B, Savidan A, Frick H, Bouchardy C, Konzelmann I, Probst-Hensch N, Ess S. A population-based study on the implementation of treatment recommendations for chemotherapy in early breast cancer. Clin Breast Cancer 2012; 12:102-9.
01.01.2012A population-based study on the implementation of treatment recommendations for chemotherapy in early breast cancer
01.01.2012Clin Breast Cancer 2012; 12:102-9
Jörger Markus, Thürlimann Beat, Savidan A, Frick H, Bouchardy C, Konzelmann I, Probst-Hensch N, Ess S
A Population-Based Study on the Implementation of Treatment Recommendations for Chemotherapy in Early Breast Cancer
Jörger M, Thürlimann B, Savidan A, Frick H, Bouchardy C, Konzelmann I, Probst-Hensch N, ess s. A Population-Based Study on the Implementation of Treatment Recommendations for Chemotherapy in Early Breast Cancer. Clin Breast Cancer 2011
02.12.2011A Population-Based Study on the Implementation of Treatment Recommendations for Chemotherapy in Early Breast Cancer
02.12.2011Clin Breast Cancer 2011
Jörger Markus, Thürlimann Beat, Savidan Anita, Frick Harald, Bouchardy Christine, Konzelmann Isabelle, Probst-Hensch Nicole, ess silvia
Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system
Matter-Walstra K, Jörger M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Value Health 2011; 15:65-71.
22.10.2011Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system
22.10.2011Value Health 2011; 15:65-71
Matter-Walstra Klazien, Jörger Markus, Kühnel Ursula, Szucs Thomas, Pestalozzi Bernhard, Schwenkglenks Matthias
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study
Jörger M, Beijnen J, Huitema A, Vincent A, Smits P, Doodeman V, Bard M, Haitjema T, Smit E, Baas P, Burgers S, Schellens J. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer 2011; 118:2466-75.
28.09.2011Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study
28.09.2011Cancer 2011; 118:2466-75
Jörger Markus, Beijnen Jos H, Huitema Alwin D R, Vincent Andrew, Smits Paul H M, Doodeman Valerie D, Bard Martin P L, Haitjema Tjeerd J, Smit Egbert F, Baas Paul, Burgers Sjaak A, Schellens Jan H M
High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?
Jörger M, Huitema A, Illerhaus G, Ferreri A. High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?. Leuk Lymphoma 2011; 52:1825-7.
10.06.2011High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?
10.06.2011Leuk Lymphoma 2011; 52:1825-7
Jörger Markus, Huitema A D R, Illerhaus G, Ferreri A J M
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
Jörger M, Beijnen J, Huitema A, Rosing H, Vainchtein L, Jansen R, Smits P, Doodeman V, Baas P, Burgers J, Schellens J. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemother Pharmacol 2011; 69:25-33.
18.05.2011Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
18.05.2011Cancer Chemother Pharmacol 2011; 69:25-33
Jörger Markus, Beijnen J H, Huitema A D R, Rosing H, Vainchtein L D, Jansen R S, Smits P H M, Doodeman V D, Baas P, Burgers J A, Schellens J H M
Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy
Jörger M, deJong D, Burylo A, Burgers J, Baas P, Huitema A, Beijnen J, Schellens J. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer 2011; 74:310-7.
29.04.2011Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy
29.04.2011Lung Cancer 2011; 74:310-7
Jörger Markus, deJong D, Burylo A, Burgers J A, Baas P, Huitema A D R, Beijnen J H, Schellens J H M
Dose-toxicity models in oncology
Jörger M. Dose-toxicity models in oncology. Expert Opin Drug Metab Toxicol 2011; 7:201-11.
13.02.2011Dose-toxicity models in oncology
13.02.2011Expert Opin Drug Metab Toxicol 2011; 7:201-11
Jörger Markus
Dose-toxicity models in oncology
Adamina M, Jörger M. Dose-toxicity models in oncology. Expert Opin Drug Metab Toxicol 2011; 7:201-211.
01.02.2011Dose-toxicity models in oncology
01.02.2011Expert Opin Drug Metab Toxicol 2011; 7:201-211
Adamina Michel, Jörger Markus
Cancer chemotherapy: targeting folic acid synthesis
Jörger M. Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res 2010; 2:293-301.
19.11.2010Cancer chemotherapy: targeting folic acid synthesis
19.11.2010Cancer Manag Res 2010; 2:293-301
Jörger Markus
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
Jörger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2010; 22:567-74.
13.09.2010Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
13.09.2010Ann Oncol 2010; 22:567-74
Jörger Markus, Matter-Walstra K, Früh Martin, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M
Predictors of state-of-the-art management of early breast cancer in Switzerland
Ess S, Jörger M, Frick H, Probst-Hensch N, Vlastos G, Rageth C, Lütolf U, Savidan A, Thürlimann B. Predictors of state-of-the-art management of early breast cancer in Switzerland. Ann Oncol 2010; 22:618-24.
12.08.2010Predictors of state-of-the-art management of early breast cancer in Switzerland
12.08.2010Ann Oncol 2010; 22:618-24
Ess S, Jörger Markus, Frick H, Probst-Hensch N, Vlastos G, Rageth C, Lütolf U, Savidan A, Thürlimann Beat
Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates
Jörger M, Templeton A, Köberle D, Engler H, Riesen W, Thürlimann B. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. Cancer Chemother Pharmacol 2010
04.08.2010Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates
04.08.2010Cancer Chemother Pharmacol 2010
Jörger Markus, Templeton Arnoud, Köberle Dieter, Engler H, Riesen W F, Thürlimann Beat
Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer
Jörger M, Riesen W, Thürlimann B. Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer. J Oncol Pharm Pract 2010
28.07.2010Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer
28.07.2010J Oncol Pharm Pract 2010
Jörger Markus, Riesen W F, Thürlimann Beat
Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
Buikhuisen W, Burgers J, Vincent A, Schellens J, Beijnen J, Smit E, Jörger M. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?. J Clin Oncol 2010; 28:e482-3; author reply e484.
06.07.2010Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
06.07.2010J Clin Oncol 2010; 28:e482-3; author reply e484
Buikhuisen Wieneke A, Burgers Jacobus A, Vincent Andrew D, Schellens Jan H M, Beijnen Jos H, Smit Egbert F, Jörger Markus
Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?
Jörger M, Thürlimann B, Huober J. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?. Ann Oncol 2010; 22:17-23.
20.06.2010Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?
20.06.2010Ann Oncol 2010; 22:17-23
Jörger Markus, Thürlimann Beat, Huober Jens
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
Jörger M, Huitema A, Krähenbühl S, Schellens J, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri A. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102:673-7.
02.02.2010Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
02.02.2010Br J Cancer 2010; 102:673-7
Jörger Markus, Huitema A D R, Krähenbühl S, Schellens J H M, Cerny Thomas, Reni M, Zucca E, Cavalli F, Ferreri A J M
The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action
Jörger M, Omlin A, Cerny T, Früh M. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Current drug targets 2010; 11:37-47.
01.01.2010The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action
01.01.2010Current drug targets 2010; 11:37-47
Jörger Markus, Omlin Aurelius, Cerny Thomas, Früh Martin
Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly - A Mini-Review
Boehm S, Rothermundt C, Hess D, Jörger M. Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly - A Mini-Review. Gerontology 2009
26.11.2009Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly - A Mini-Review
26.11.2009Gerontology 2009
Boehm S, Rothermundt Christian, Hess Dagmar, Jörger Markus